Log in

NASDAQ:ONVO - Organovo Stock Price, Forecast & News

$0.46
0.00 (0.00 %)
(As of 01/20/2020 08:52 AM ET)
Today's Range
$0.44
Now: $0.46
$0.46
50-Day Range
$0.36
MA: $0.46
$0.62
52-Week Range
$0.22
Now: $0.46
$1.18
Volume474,736 shs
Average Volume618,632 shs
Market Capitalization$59.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 million
Book Value$0.30 per share

Profitability

Net Income$-26,640,000.00
Net Margins-774.47%

Miscellaneous

Employees70
Market Cap$59.72 million
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.


Organovo (NASDAQ:ONVO) Frequently Asked Questions

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, November, 7th. The medical research company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The medical research company had revenue of $1.23 million for the quarter, compared to analyst estimates of $0.79 million. Organovo had a negative net margin of 774.47% and a negative return on equity of 74.72%. View Organovo's Earnings History.

When is Organovo's next earnings date?

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Organovo.

What is the consensus analysts' recommendation for Organovo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.

Has Organovo been receiving favorable news coverage?

News stories about ONVO stock have trended positive on Monday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Organovo.

Are investors shorting Organovo?

Organovo saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,480,000 shares, a decline of 25.6% from the December 15th total of 1,990,000 shares. Based on an average daily trading volume, of 674,700 shares, the short-interest ratio is currently 2.2 days. Approximately 1.2% of the shares of the stock are short sold. View Organovo's Current Options Chain.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

Who are Organovo's key executives?

Organovo's management team includes the folowing people:
  • Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
  • Mr. Craig Kussman, Chief Financial Officer (Age 60)
  • Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Paul Gallant, Gen. Mang. (Age 54)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $0.46.

How big of a company is Organovo?

Organovo has a market capitalization of $59.72 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.

What is Organovo's official website?

The official website for Organovo is http://www.organovo.com/.

How can I contact Organovo?

Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


MarketBeat Community Rating for Organovo (NASDAQ ONVO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  178 (Vote Underperform)
Total Votes:  349
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel